초록 ▼

Disclosed are methods for identifying genetic mosaicisms in cell populations. Suitable cell populations include, e.g., biopsy or body fluid samples or cultures of cancer cells. The method includes performing array-based comparative genomic hybridization (CGH), wherein a plurality of cloned genomic n

Disclosed are methods for identifying genetic mosaicisms in cell populations. Suitable cell populations include, e.g., biopsy or body fluid samples or cultures of cancer cells. The method includes performing array-based comparative genomic hybridization (CGH), wherein a plurality of cloned genomic nucleic acid segments is provided in a plurality of identical replicas, each cloned segment immobilized to a discrete and known spot on a substrate surface to form the array, and the cloned genomic nucleic acid segments comprise a substantially complete first genome of a known first karyotype. The invention also provides methods for optimizing performance of an array-based comparative genomic hybridization (CGH).

대표청구항 ▼

What is claimed is: 1. A method of detecting a degree of genetic mosaicism in a cell population by performing an array-based comparative genomic hybridization (CGH), wherein an array comprising a plurality of cloned genomic nucleic acid segments is provided in a plurality of identical replicas, eac

What is claimed is: 1. A method of detecting a degree of genetic mosaicism in a cell population by performing an array-based comparative genomic hybridization (CGH), wherein an array comprising a plurality of cloned genomic nucleic acid segments is provided in a plurality of identical replicas, each cloned segment immobilized to a discrete and known spot on a substrate surface to form the array, the cloned genomic nucleic acid segments comprising a substantially complete first genome of a known first karyotype, the method comprising: (a) contacting replicas of the array with mixtures of a first nucleic acid sample and a second nucleic acid sample and fractional dilutions of the second sample, wherein the first sample comprises a plurality of genomic nucleic acid segments comprising a substantially complete complement of the first genome labeled with a first detectable label, the second sample-comprises a plurality of genomic nucleic acid segments comprising a substantially complete complement of the second genome labeled with a second detectable label, and the karyotype of the second sample is known and is different from that of the first sample; (b) contacting further replicas of the array with mixtures of the first nucleic acid sample and a third nucleic acid sample and fractional dilutions of the third sample, wherein the third sample comprises a genomic nucleic acid sample with an unknown karyotype and is labeled with the second detectable label, and the genomic nucleic acid of the third sample comprises a substantially complete complement of genomic nucleic acid of a third genome from a test cell or a tissue sample, wherein the contacting is under conditions wherein the nucleic acid in the mixtures of each of the first and second samples and the first and third samples can specifically hybridize to the genomic nucleic acid segments immobilized on the array; (c) measuring the amount of first label and second label on each spot for each respective contacted array and determining the karyotype of each dilution fraction by comparative genomic hybridization; and, (d) selecting which fractional dilution karyotype determination of the second sample most closely determines the known karyotype, and selecting data for the same fractional dilution of the third sample to determine the karyotype of the third sample, thereby determining the degree of genetic mosaicism in the-cell population. 2. The method of claim 1, wherein the cell population comprises human cells. 3. The method of claim 1, wherein the cell population is derived from an individual suspected of having a chromosomal abnormality. 4. The method of claim 1, wherein the cell population is selected from the group of samples of a body fluid; a tissue; a biopsy; a blood sample; an amniotic fluid; a chorionic villus sample; an embryonic cell; and an embryonic tissue. 5. The method of claim 4, wherein the body fluid or tissue sample comprises a cancer cell or a tumor cell sample. 6. The method of claim 1, wherein at least one of the first, second and third genomes comprises a mammalian genome. 7. The method of claim 6, wherein the first, second and third mammalian genomes comprise human genomes. 8. The method of claim 1, wherein a cloned nucleic acid segment is cloned in a construct comprising an artificial chromosome. 9. The method of claim 8, wherein the artificial chromosome comprises a bacterial artificial chromosome (BAC). 10. The method of claim 8, wherein the artificial chromosome is selected from the group consisting of a human artificial chromosome (HAC), a yeast artificial chromosome (YAC), a transformation-competent artificial chromosome (TAC), and a bacteriophage P1-derived artificial chromosome (PAC). 11. The method of claim 1, wherein a cloned nucleic acid segment is cloned in a construct comprising a vector selected from the group consisting of a cosmid vector, a plasmid vector and a viral vector. 12. The method of claim 8, wherein the cloned nucleic acid segment is between about 50 kilobases to about 500 kilobases in length. 13. The method of claim 12, wherein the cloned nucleic acid segment is between about 100 kilobases to about 400 kilobases in length. 14. The method of claim 13, wherein the cloned nucleic acid segment is about 300 kilobases in length. 15. The method of claim 1, wherein the karyotype of at least one of the first genome and the second genome is determined by conventional G-banding analysis, FISH or SKY. 16. The method of claim 1, wherein the detectable label comprises a fluorescent label. 17. The method of claim 16, wherein the fluorescent label comprises Cy5�� or equivalent. 18. The method of claim 16, wherein the fluorescent label comprises Cy3�� or equivalent. 19. The method of claim 16, wherein the fluorescent label comprises a rhodamine, a fluorescein or an aryl-substituted 4,4-difluoro-4-bora-3a, 4a-diaza-s-indacene dye or equivalents. 20. The method of claim 1, wherein the array-immobilized genome comprises a wild type genome. 21. The method of claim 20, wherein the first sample comprises a wild type genome. 22. The method of claim 1, wherein the second sample comprises a cancer cell population. 23. The method of claim 1, wherein the second sample comprises a mosaic karyotype. 24. The method of claim 23, wherein the second sample comprises a mosaic karyotype comprising two or more cell subpopulations, wherein each subpopulation comprises a different karyotype. 25. The method of claim 1, wherein the array-immobilized genomic nucleic acid segments in a first spot are non-overlapping in sequence compared to the array-immobilized genomic nucleic acid segments in a second spot. 26. The array of claim 25, wherein the array-immobilized genomic nucleic acid segments in a spot are non-overlapping in sequence compared to the array-immobilized genomic nucleic acid segments all of other genomic nucleic acid-comprising spots on the array. 27. The method of claim 1, wherein each cloned genomic nucleic acid segment is spotted in duplicate on the array. 28. The method of claim 1, wherein the array-immobilized genomic nucleic acid are covalently bound to the substrate surface. 29. The method of claim 28, wherein the array-immobilized genomic nucleic acid are covalently bound to a compound having the general formula: R1--X--R2, wherein R1 is a cyclic ether; an aldehyde, or a chloromethylphenyl moiety; X is a moiety chemically suitable for linking the R1 moiety to the R2 moiety, and the R2 moiety has the general formula wherein R3, R4 and R5 comprise identical or different alkoxy group or chioro groups. 30. The method of claim 1, wherein the array-immobilized genomic nucleic acid are covalently bound to a compound having the general formula: R1--X--R2, wherein R1 is an amino group, R2 is an alkoxysilane group or a chlorohalide group; and X is a moiety chemically suitable for linking the R1 group and the R2 group. 31. The method of claim 1, wherein the array-immobilized genomic nucleic acid are covalently bound to a compound having the general formula description="In-line Formulae" end="lead"R1--X--Si (OR2)m(Cl)n(R)k,description="In-line Formulae" end="tail" wherein m+k is the integer 3, and n can be 0 if m is greater than 0, or n+k is the integer 3 and m can be 0 if n is greater than 0; X is an inert linker; R1 comprises a group reactive toward the biological molecule; R is an alkyl group; and, R2 is an alkyl group. 32. The method of claim 1, comprising use of a device that can measure which detectable labels are on which spots on the substrate surface. 33. The method of claim 32, wherein the device comprises a charge-coupled device (CCD). 34. The method of claim 33, wherein the device is capable of multicolor fluorescence imaging. 35. The method of claim 1, comprising use of a computer processor to analyze multicolor fluorescence imaging data. 36. The method of claim 1, further comprising use of a computer and a computer program algorithm to interpret data imaged from the array and display results of a karyotype analysis. 37. The method of claim 1, further comprising contacting the fractions of the sample under varying conditions. 38. The method of claim 37, wherein varying the conditions comprises varying a condition selected from temperature used in hybridization conditions; temperature used in wash conditions for each fraction; osmolarity of a hybridization buffer; osmolarity of a wash buffer; time each fraction is contacted; time before each fraction is washed; time during which each fraction is washed; humidity of the hybridization conditions; time each fraction is contacted to the array before reading; concentration of the nucleic acid; and size of the nucleic acid. 39. The method of claim 1, wherein said cell population is derived from an individual suspected of having a disease or condition associated with a karyotype abnormality. 40. The method of claim 39, wherein the disease or condition comprises a cancer.